Creating the next generation of glycomaterials for gene and drug delivery applications-Lab2M

我们的计划是将最先进的功能修饰的糖共聚物和糖偶联物商业化，用于药物/基因输送载体和细胞治疗。我们开发了独特的合成方法，使得高精度设计新的聚合物结构具有更好的结合亲和力。我们已经合成了定义明确的不同分子量、组成和结构的糖共聚物，并评估了它们作为基因/药物输送载体和细胞支架的潜力，使得具有复杂结构-活性关系(酸可降解性、氧化还原响应、温度-响应)的悬挂式生物相容部分易于连接。使用天然多糖进行基因传递减少了对过量阳离子电荷的需求，从而降低了系统的毒性，因为碳水化合物通过氢键缩合了寡核苷酸。这些碳水化合物单元还与特定的细胞受体(多糖)相互作用，并作为靶向试剂，而不需要进一步的修饰。

Our plan is to commercialized state-of-the-art functionally modified glycopolymers and glycoconjugates fortheir use as drug/gene delivery vehicles and cell therapies. We have developed unique synthesis approachesthat have allowed the design of new polymeric architectures in high precision with improved binding affinity.Well-defined glycopolymers with varying molecular weights, compositions and architectures have beensynthesized and evaluated their potential as gene/drug delivery vectors and cell scaffolds, allowing faciletailoring with pendant biocompatible moieties with complex structure-activity relationships (acid degradability,redox response, temperature-response). The use of natural polysaccharides for gene delivery has reduced theneed for an excess cationic charge, hence decreasing the system's toxicity, as carbohydrates condensed theoligonucleotides via hydrogen bonding. These carbohydrate units also interact with specific cell receptors(glycans) and serve as targeting agents without a need for further modifications.